Key Points
- Insider sale: Director Francis Lo sold 79,590 shares on Jan. 12 at an average price of $17.73 for about $1.41M, trimming his position by 20.12% to 315,978 shares (valued ~ $5.60M).
- Pattern of disposals: Lo has executed multiple recent sales, including 113,890 shares on Dec. 15 at $15.57 (≈ $1.77M) and smaller sales on Dec. 22 and Jan. 2, signaling ongoing insider selling activity.
- Company snapshot: ADPT trades near $18 with a $2.75B market cap; last quarter revenue surged 102% YoY to $93.97M but the company remains unprofitable, and analysts have a consensus "Moderate Buy" with an average target of $17.11.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $18.00, for a total value of $77,220.00. Following the sale, the chief financial officer directly owned 216,637 shares in the company, valued at approximately $3,899,466. This trade represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kyle Piskel also recently made the following trade(s):
- On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.50, for a total value of $3,174,990.00.
- On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total value of $3,343.90.
Adaptive Biotechnologies Price Performance
Shares of ADPT stock opened at $18.04 on Thursday. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76. The stock has a fifty day moving average price of $16.50 and a 200 day moving average price of $14.44. The stock has a market cap of $2.75 billion, a P/E ratio of -33.41 and a beta of 2.18.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $93.97 million during the quarter, compared to analysts' expectations of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business's revenue was up 102.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.22) EPS. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on ADPT shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. BTIG Research increased their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. Piper Sandler lifted their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an "overweight" rating in a report on Wednesday, October 15th. Cowen restated a "buy" rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Finally, Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an "equal weight" rating and a $21.00 target price for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus target price of $17.11.
Read Our Latest Report on Adaptive Biotechnologies
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC bought a new stake in shares of Adaptive Biotechnologies during the third quarter worth approximately $30,000. Smartleaf Asset Management LLC grew its holdings in Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company's stock worth $59,000 after acquiring an additional 3,371 shares during the period. Quadrant Capital Group LLC acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at $133,000. Keybank National Association OH bought a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth $155,000. Finally, Caprock Group LLC bought a new stake in Adaptive Biotechnologies in the third quarter valued at about $163,000. Institutional investors own 99.17% of the company's stock.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
